Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05045716 · ClinicalTrials.gov registry record · Phase 1
A Study of Subcutaneous Lecanemab in Healthy Participants
A Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT05045716 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 60 participants.
The verdict
NCT05045716, a Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine the absolute bioavailability and pharmacokinetic (PK) profile of a single dose of lecanemab when administered subcutaneously (SC) in healthy participants.
Interventions
- DRUG Lecanemab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-09-07 |
| Est. Completion | 2021-12-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05045716
The ClinicalTrials.gov registry entry for NCT05045716 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lecanemab is the first listed.
NCT05045716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05045716 about?
NCT05045716 is a clinical study titled "A Study of Subcutaneous Lecanemab in Healthy Participants". The primary purpose of this study is to determine the absolute bioavailability and pharmacokinetic (PK) profile of a single dose of lecanemab when administered subcutaneously (SC) in healthy participants.
What is the current status of trial NCT05045716?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2021-09-07. Estimated completion is 2021-12-07.
What interventions are being tested in trial NCT05045716?
The interventions under investigation include: Lecanemab (DRUG).
Who is sponsoring clinical trial NCT05045716?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.